AstraZeneca and Merck Announce Phase 3 GY004 for Cediranib and LYNPARZA in Platinum-Sensitive Relapsed Ovarian Cancer Did Not Meet the Primary Endpoint of Progression-Free Survival vs. Platinum-Based Chemotherapy